Html code will be here
Scientific Organisers
Institute of Translational Medicine and Biotechnology, Expert and Analytical Centre for Horizon Scanning in Healthcare, and Department of Technological Leadership (Sechenov University)
About the Conference
The conference ‘Horizon Scanning in Healthcare: New Therapeutic Modalities — From Platforms to Clinical Practice' will explore emerging therapeutic platforms poised to shape the next phase of healthcare, including gene and cell therapies, mRNA-based approaches, oligonucleotide therapeutics, genome and RNA editing technologies, and other innovations that are transforming the future landscape of medicine.
The discussion will focus not only on the scientific potential of these modalities, but also on the assessment of emerging technologies, priority-setting, infrastructure readiness, regulatory pathways, workforce capacity, financing, and patient access to innovative therapies. Particular attention will be given to international experience, including approaches to creating the conditions needed for the development, assessment, prioritisation and adoption of new therapeutic platforms in the Middle East and China, as well as the roles of universities, research centres, industry, regulators and the healthcare system in advancing these technologies and ensuring access to them.
The conference will bring together representatives of federal government bodies, regulatory and expert organisations, research and academic communities, clinical centres, developers and manufacturers of medicinal products and medical technologies, investors, and companies interested in advancing an innovative healthcare ecosystem. It will provide a professional forum for discussing technology development priorities over the next 5−10 years and formulating proposals to improve the conditions for integrating new therapeutic solutions into the healthcare system.
Registration
Programme
Horizon Scanning in Healthcare: New Therapeutic Modalities — From Platforms to Clinical Practice
DATE:
30 October 2026
30 October 2026
Sechenov University Congress Centre,
8 Trubetskaya Street, Moscow
8 Trubetskaya Street, Moscow
View full programme
Participant Registration and Welcome Coffee
- Participant registration
- Welcome coffee
Plenary Session: Medical Universities as Hubs for Healthcare Development
Moderator: Vadim V. Tarasov
Discussion topics:
Invited participants: Representatives of the Ministry of Health of the Russian Federation, medical universities, industry, financial and investment institutions, National Medical Research Centres and university hospitals, and patient organisations.
Discussion topics:
- In which areas can medical universities provide expert support for the development of healthcare and the pharmaceutical industry?
- How can government and the healthcare system articulate their demand for innovation to researchers, clinicians, industry and investors?
- How should priorities for medical technology development be set in light of population needs, public health objectives and sustainable financing?
- How should unmet medical need be defined, including priority disease areas, patient groups and the expected contribution of new solutions to life expectancy and quality of life?
- How can a medical university serve as an expert platform for collaboration among government, the clinical community, industry, investors, patients and researchers?
- How can the pathway from scientific discovery to clinical practice be designed so that innovations respond to healthcare system needs and have a clear route to implementation?
Invited participants: Representatives of the Ministry of Health of the Russian Federation, medical universities, industry, financial and investment institutions, National Medical Research Centres and university hospitals, and patient organisations.
Panel Session 1. Horizon Scanning in Healthcare: International Practices and a Russian Model
Discussion topics:
Invited participants: Representatives of the National Institute for Health Research at Tehran University of Medical Sciences, Iran; the Department of Health – Abu Dhabi, United Arab Emirates; Fudan University and the National Health Commission, China; and Sechenov University, Russia
- What model should be developed for a university-based horizon scanning centre in Russia, and which international practices could be adapted?
- What outputs should a horizon scanning centre produce: signal reports, early assessments, policy briefs, dashboards, priority lists of technologies or recommendations for further assessment?
- Which criteria should guide technology prioritisation: unmet medical need, expected clinical benefit, maturity of the evidence, budget impact, infrastructure readiness or implementation risks?
- Which signal sources are most important: clinical trials, scientific publications, patents, regulatory decisions, investment trends, real-world data (RWD) or international databases?
- How do different countries organise horizon scanning, and how is it linked to health technology assessment (HTA), regulatory decision-making, procurement, financing and clinical translation?
Invited participants: Representatives of the National Institute for Health Research at Tehran University of Medical Sciences, Iran; the Department of Health – Abu Dhabi, United Arab Emirates; Fudan University and the National Health Commission, China; and Sechenov University, Russia
Coffee Break
Panel Session 2. New Therapeutic Modalities: Gene and Cell Technologies — From Research Platforms to Clinical Practice
Discussion topics:
Invited participants: Representatives of the Ministry of Industry and Trade of the Russian Federation; National Medical Research Centres, including the National Medical Research Center for Hematology and the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Sechenov University; developers and manufacturers of gene and cell therapies; pharmaceutical and biotechnology companies; and clinicians.
- Which gene, cell and related technologies are likely to shape clinical practice in the near term: CAR-T therapies, in vivo and ex vivo gene therapies, cell-based products, RNA and oligonucleotide therapeutics, and genome editing?
- Which clinical areas should be prioritised for early assessment: haemato-oncology, rare diseases, inherited disorders, immune-mediated conditions and severe chronic diseases?
- How do hospital-based models, personalised manufacturing and industrially manufactured products compare, including requirements for GMP compliance, quality control, logistics, data comparability and long-term monitoring?
- What infrastructure is needed for implementation: expert centres, laboratories, biobanks, patient registries, coordinated patient pathways, multidisciplinary teams and long-term follow-up?
- What evidence is required to support decisions on the adoption and funding of new therapeutic modalities when uncertainty is high and data are limited?
Invited participants: Representatives of the Ministry of Industry and Trade of the Russian Federation; National Medical Research Centres, including the National Medical Research Center for Hematology and the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Sechenov University; developers and manufacturers of gene and cell therapies; pharmaceutical and biotechnology companies; and clinicians.
Coffee Break
Closing discussion. Artificial Intelligence in Healthcare: Digital Data, Evidence and Trust in Decision-Making
Discussion topics:
Invited participants: Representatives of the Ministry of Health of the Russian Federation, financial institutions and Sechenov University; AI developers; clinicians; experts in big data, real-world data (RWD) and real-world evidence (RWE); and experts in ethics and data security.
- Which AI applications should fall within the scope of horizon scanning: diagnosis, screening, risk prediction, clinical decision support, patient pathway coordination and resource management?
- How should the evidence supporting AI be assessed, including data quality and representativeness, clinical validation, reproducibility, interpretability, safety and post-market surveillance?
- How can a medical university serve as a testbed for AI solutions by providing clinical expertise, access to data, controlled testing environments, independent evaluation, methodological guidance and user training?
- How can digital data and AI inform decision-making by the Ministry of Health, university hospitals, payers, investors, industry and horizon scanning centres?
- How can trust in AI be built through algorithmic transparency, data protection, accountability, ethical frameworks and managed adoption into clinical practice?
Invited participants: Representatives of the Ministry of Health of the Russian Federation, financial institutions and Sechenov University; AI developers; clinicians; experts in big data, real-world data (RWD) and real-world evidence (RWE); and experts in ethics and data security.
Conference Conclusions and Proposals for the Final Resolution
- Key conclusions on the role of medical universities, horizon scanning, new therapeutic modalities and artificial intelligence.
- Proposals for further guidance documents, educational programmes, international collaboration and pilot projects.
The programme is provisional and may be updated with regard to the speakers, moderators and final wording of the session topics.
Contacts
ECONiX Research LLC
Registered address:
27 Zelenogradskaya Street, Building 2, Premises 12N, Moscow, Russia
27 Zelenogradskaya Street, Building 2, Premises 12N, Moscow, Russia
Participation enquiries:
